Jeffrey Settleman
- Oncology top 0.05%
- HER2/EGFR in Cancer Research 22
- Cancer Research top 0.2%
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations 32
- Cell Biology top 0.1%
- Cellular Mechanics and Interactions 24
- Molecular Biology top 0.1%
- Protein Kinase Regulation and GTPase Signaling 48
- Melanoma and MAPK Pathways 17
- PI3K/AKT/mTOR signaling in cancer 17
- Cancer therapeutics and mechanisms 13
-
- Cell Adhesion Molecules Research 18
- Co-authors
- Daniel A. HaberDaphne W. BellSreenath V. SharmaRaffaella SordellaJeffrey A. EngelmanThomas J. LynchA. John IafrateUltan McDermott
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Jeffrey Settleman
158 papers receiving 23.0k citations
Hit Papers
Peers
Comparison fields: 5 of 144
- Oncology 10.4k
- Cancer Research 3.8k
- Pulmonary and Respiratory Medicine 7.7k
- Cell Biology 3.7k
- Molecular Biology 14.0k
Countries citing papers authored by Jeffrey Settleman
This map shows the geographic impact of Jeffrey Settleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Settleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Settleman more than expected).
Fields of papers citing papers by Jeffrey Settleman
This network shows the impact of papers produced by Jeffrey Settleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Settleman. The network helps show where Jeffrey Settleman may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jeffrey Settleman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 19 | |
| 2 | 2014 | 125 | |
| 3 | 2013 | 61 | |
| 4 | 2013 | 110 | |
| 5 | 2013 | 35 | |
| 6 | 2012 | 87 | |
| 7 | EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenibbreakdown → | 2012 | 767 |
| 8 | 2011 | 334 | |
| 9 | 2011 | 287 | |
| 10 | 2011 | 96 | |
| 11 | 2009 | 83 | |
| 12 | 2009 | 30 | |
| 13 | Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKbreakdown → | 2009 | 1463 |
| 14 | 2008 | 92 | |
| 15 | 2008 | 405 | |
| 16 | 2008 | 72 | |
| 17 | 2008 | 75 | |
| 18 | 2008 | 312 | |
| 19 | 2007 | 150 | |
| 20 | Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibbreakdown → | 2005 | 774 |
About Jeffrey Settleman
Jeffrey Settleman is a scholar working on Immunology and Allergy, Cell Biology and Oncology, having authored 158 papers that have together received 23.5k indexed citations. Recurring topics across this work include Protein Kinase Regulation and GTPase Signaling (48 papers), Lung Cancer Treatments and Mutations (32 papers), Cellular Mechanics and Interactions (24 papers), HER2/EGFR in Cancer Research (22 papers), Cell Adhesion Molecules Research (18 papers), Melanoma and MAPK Pathways (17 papers), PI3K/AKT/mTOR signaling in cancer (17 papers) and Cancer therapeutics and mechanisms (13 papers). The work is most often cited by research in Oncology (10.4k citations), Cancer Research (3.8k citations) and Pulmonary and Respiratory Medicine (7.7k citations). Jeffrey Settleman has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Daniel A. Haber, Daphne W. Bell, Sreenath V. Sharma, Raffaella Sordella, Jeffrey A. Engelman, Thomas J. Lynch, A. John Iafrate, Ultan McDermott, Margaret P. Quinlan and Ryan B. Corcoran. Their work appears in journals such as Cancer Research, Molecular and Cellular Biology, Cell, Journal of Biological Chemistry and Current Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.